Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. companies skeptical of corporate China's advances

Published 04/27/2016, 01:36 AM
Updated 04/27/2016, 01:40 AM
© Reuters. A man walks into the 'W London' hotel in Leicester Square in central London

By Greg Roumeliotis and Mike Stone

(Reuters) - Chinese life sciences entrepreneur Wei Zhou submitted a $1.5 billion bid for U.S. gene testing company Affymetrix last month - topping a $1.3 billion agreed acquisition by Thermo Fisher Scientific Inc (N:TMO). A few days later, he got an unusual deadline.

Affymetrix's CEO Frank Witney called Zhou, a former Affymetrix executive who had partnered with Shanghai government-backed investment firm SummitView Capital on his offer. Witney gave him five days to put the full purchase price and the breakup fee that would be owed Thermo Fisher in an escrow account.

Suitors of U.S. companies don't typically face such demands. But Affymetrix's board of directors decided that, because Zhou's consortium had no significant U.S. assets, the company would have little recourse if the deal fell through.

Zhou's investment bankers responded that only the consortium's break-up fee of $100 million could be escrowed, and that would take weeks. Affymetrix decided to stick with Thermo Fisher.

The deliberations, described in regulatory filings, underscore the challenges many Chinese buyers face in convincing U.S. companies to make a deal, especially when competing against a U.S. company.

Traditionally, the biggest hurdle has been the Committee on Foreign Investment in the United States (CFIUS), a government panel that scrutinizes deals for national security threats.

But as Chinese acquisitions picked up this year, U.S. dealmakers also are paying attention to financing and regulatory risk from China.

The biggest illustration of that risk was China-based Anbang Insurance Group Co's surprise withdrawal last month of its $14 billion bid for Starwood Hotels & Resorts Worldwide Inc (N:HOT), which had trumped a rival offer from Marriott International Inc (O:MAR).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

U.S. companies want to make sure that Chinese suitors have approval of key Chinese agencies, such as the ministry of commerce (MOFCOM), and that financing is reliable.

"If the buyer faces uncertainty over their financing or approval from MOFCOM, their bid won’t be competitive without a substantial reverse break-up fee," said Robert Profusek, head of mergers and acquisitions at law firm Jones Day.

When Chinese aviation and shipping conglomerate HNA Group clinched a deal in February to buy U.S. electronics distributor Ingram Micro Inc (N:IM) for about $6 billion, it agreed to deposit $400 million in an escrow account payable to Ingram Micro should the deal fail to receive regulatory or antitrust approval.

This "reverse termination" fee of 6.6 percent of the deal's value illustrates the higher reassurance demands for Chinese buyers. By comparison, U.S. acquirers typically offer about 3 percent.

COMPETING OFFERS

When Chinese suitors attempt to acquire U.S. companies that have competing offers, it can be difficult to get them to abandon a pending agreement.

For example, Chinese crane maker Zoomlion Heavy Industry Science and Technology Co (HK:1157) has spent six months trying to convince U.S. peer Terex Corp (N:TEX) to abandon its merger agreement with Finland's Konecranes (HE:KCR1V) for its bid, which now exceeds $3.4 billion.

Still, there is a logic to moving in on pending deals, dealmakers say. Some Chinese buyers, lacking the resources and confidence to make their own offers, piggyback on diligence performed by others.

When negotiating in a less competitive environment, Chinese companies have driven hard bargains. Richard Handler, CEO of investment bank Jefferies LLC, which has advised 10 U.S. companies in sales to Chinese buyers totaling $6 billion, said in an interview his investment bankers and clients have found Chinese buyers to be "tough negotiators."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

When a Chinese consortium led by ink cartridge chip maker Apex Technology Co Ltd reached a deal last week to buy Lexmark International Inc (N:LXK) for $3.6 billion, it secured it with a termination fee of $150 million - 4 percent of the deal's value - through a letter of credit from the New York branch of Bank of China, rather than an escrow.

Lexmark had been exploring a sale for more than six months and was unhappy with previous acquisition offers, said sources close to the company who spoke on condition of anonymity. So, it was in a weaker negotiating position than U.S. companies demanding full escrow.

There is little evidence Chinese acquirers are paying more on average. Thomson Reuters has tracked 66 deals involving U.S. acquirers and buyers this year. The average ratio of deal value to 12-month earnings before interest, tax, depreciation and amortization on those deals was 11.3. For six Chinese purchases, it was 9.9.

It can be easier for private equity firms than publicly traded companies to make deals with Chinese buyers because they don't face the threat of shareholder lawsuits if things go wrong.

Some private equity firms have sought to take advantage by acting as a "bridge" between public U.S. companies and Chinese acquirers. Anbang, for example, agreed to acquire Strategic Hotels & Resorts Inc from Blackstone Group LP (N:BX) for about $6.5 billion in March, three months after Blackstone took it private for $6 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.